Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Maintenance therapy and MRD in myeloma

Elena Zamagni • 10 Sep 2021
IMW 2021
Multiple Myeloma

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, outlines the role of maintenance therapy and measurable residual disease (MRD) in the treatment of patients with multiple myeloma, comparing approaches for standard-risk and high-risk patients. Dr Zamagni explains the importance of achieving MRD negativity prior to maintenance therapy in standard-risk patients, and the benefits of evaluating MRD negativity after induction in patients with high-risk myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Elena Zamagni

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:23
Combining MRD assays with functional imaging in multiple myeloma
Elena Zamagni • 28 Sep 2023
1:21
The impact of MRD standardized assessment by FDG-PET/CT in patients enrolled in the FORTE trial
Elena Zamagni • 28 Sep 2023
2:29
The role of various imaging techniques in multiple myeloma & the importance of optimizing these
Elena Zamagni • 28 Sep 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals